NRx Pharmaceuticals, Inc. (NRXP) Q1 2025 Earnings Call Transcript

Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?

Here is how ANI Pharmaceuticals (ANIP) and Agenus (AGEN) have performed compared to their sector so far this year.

ANI Pharmaceuticals: A Short-Term Buying Opportunity

Buy 4 Low-Beta Stocks ANIP, LRN, MASS & CTGO as Tariff Woes Continue

It is imperative to build a portfolio of low-beta stocks in a volatile market. ANI Pharmaceuticals, Stride, 908 Devices, & Contango are well-poised to gain.

Tariff Woes? Play Safe With 4 Low-Beta Stocks: ANIP, EXE, AVA & CTGO

It is imperative to build a portfolio of low-beta stocks in a volatile market. ANI Pharmaceuticals, Expand Energy, Avista & Contango are well-poised to gain.

Zacks.com featured highlights include HIS, ANI Pharmaceuticals, Pediatrix Medical, Fresenius Medical Care and LendingTree

HIS, ANI Pharmaceuticals, Pediatrix Medical, Fresenius Medical Care and LendingTree are part of the Zacks Screen of the Week article.

NRx Pharmaceuticals, Inc. (NRXP) Q4 2024 Earnings Call Transcript

ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label

BAUDETTE, Minn., March 14, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for ILUVIEN (fluocinolone acetonide intravitreal implant) that includes an indication for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). The approval also includes other updates to the label including to the Warnings and Precautions s...

Zacks.com featured highlights include ANI Pharmaceuticals, Dana, Pitney Bowes, Priority Technology and Kingstone

ANI Pharmaceuticals, Dana, Pitney Bowes, Priority Technology and Kingstone are part of the Zacks Screen of the Week article.

ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance

BAUDETTE, Minn., Feb. 28, 2025 (GLOBE NEWSWIRE) --  ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the fourth quarter and full year ended December 31, 2024.

ANI Pharmaceuticals to Present at Raymond James’ Institutional Investors and Leerink Partners Global Healthcare Conferences in March

PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and select members of senior management, will present at two upcoming investor conferences as follows:

Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?

Here is how ANI Pharmaceuticals (ANIP) and Doximity (DOCS) have performed compared to their sector so far this year.

ANI Pharmaceuticals: More Than Just A Generics Company

ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference

PRINCETON, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will host a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024 at 3pm EST in NYC.

NRx Pharmaceuticals, Inc. (NRXP) Q3 2024 Earnings Call Transcript

ANI Pharmaceuticals, Inc. (ANIP) Q3 2024 Earnings Call Transcript

ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance

BAUDETTE, Minn., Nov. 08, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the three months ended September 30, 2024.

Vanda Pharmaceuticals Inc. (VNDA) Q3 2024 Earnings Call Transcript

ANI Pharmaceuticals Is Acting Like It Is Being Acquired

ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.06%

PRINCETON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched Estradiol Gel, 0.06%. ANI’s Estradiol Gel, 0.06% is the generic version of the reference listed drug (RLD) EstroGel® Gel, 0.06%.

Cycle Pharmaceuticals Stands By $488 Million Offer for Vanda

Cycle Pharmaceuticals Ltd. is still interested in acquiring Vanda Pharmaceuticals Inc. after one of Vanda’s drugs failed to receive regulatory approval.

ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market

Aresus gibt Strategie zur Erweiterung der Produktionskapazitäten für den pharmazeutischen Wirkstoff Sinecatechins bekannt

Dermago GmbH: Strausberg (ots) - Die Aresus Pharma GmbH, ein Unternehmen der DERMAGO-Gruppe, Deutschland, gibt den Abschluss einer Kooperationsvereinbarung mit ANI Pharmaceuticals, Inc., USA, zur Etablierung eines neuen Herstellers für den pharmazeutischen ...

ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences

PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP) today announced the completion of its previously announced acquisition of Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”).

ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences

PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announced today that the Company has initiated closing logistics for the previously announced acquisition of Alimera Sciences, Inc. (Nasdaq: ALIM).

ANI Pharmaceuticals, Alimera Sciences deal set to close Monday

ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger

ANI and Alimera Scheduled the Closing for September 16, 2024 ANI and Alimera Scheduled the Closing for September 16, 2024

ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences

PRINCETON, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP) today provided an update on the status of the completion of its previously announced acquisition of Alimera Sciences, Inc. (“Alimera”) (Nasdaq: ALIM).

NRx Pharmaceuticals, Inc. (NRXP) Q2 2024 Earnings Call Transcript